Latest News
-
Ridgefield, Conn. – Boehringer Ingelheim today announced results from an analysis of the SENSCIS®-ON trial. SENSCIS-ON is an open-label extension trial of the Phase III SENSCIS® study to assess the long-term tolerability and safety of Ofev® (nintedanib) in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD). The study also evaluated... -
Posaconazole was non-inferior to voriconazole for the primary treatment of invasive aspergillosis, according to an international, randomized, double-blind, double-dummy, controlled non-inferiority trial published in the Lancet. Between October 25, 2013, and September 10, 2019, investigators randomly assigned 585 participants to receive either posaconazole or voriconazole. In the posaconazole group, 288 participants...
-
SYDNEY – Australian pharmaceutical group Phebra (‘Company’) congratulates the Australasian Leukaemia and Lymphoma Group (ALLG) on the release of their abstract EP433 at the virtual European Hematology Association (EHA) 2021 Conference. The abstract builds on the initial bioequivalence data from the first phase of the trial, published at EHA in June...
Videos
Rare disease spotlight
All patients deserve access to affordable care.
But discriminatory healthcare metrics like quality-adjusted-life-years (QALY) allow health insurance plans to refuse coverage for rare disease treatments.
http://ow.ly/2fVL50DMuiP
Check out my interview with @CNN!
https://www.cnn.com/2021/05/13/health/processed-food-chronic-disease-wellness/index.html
"I’ll never forget the blindingly bright lightbulb moment I had when I realized my fibromyalgia symptoms had always been chronic porphyria."
http://ow.ly/Mb6N50EEP3H
We are excited to introduce you to Good Dogg Beverage, a new philanthropic company that makes premium hard seltzer to support causes they care about, like http://KIF1A.ORG. Learn more on the http://KIF1A.ORG blog!
https://www.kif1a.org/blog/good-dogg-beverage-partners-with-kif1a-org-to-support-our-mission/